50 related articles for article (PubMed ID: 17438099)
1. From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development.
Doroshow DB; Doroshow JH
Cancer J; 2019; 25(4):245-253. PubMed ID: 31335388
[TBL] [Abstract][Full Text] [Related]
2. Design and reporting of phase III oncology trials with prospective biomarker validation.
Liang F; Peng L; Wu Z; Giamas G; Stebbing J
J Natl Cancer Inst; 2023 Feb; 115(2):174-180. PubMed ID: 36448689
[TBL] [Abstract][Full Text] [Related]
3. Design of phase II oncology trials evaluating combinations of experimental agents.
Sharon E; Foster JC
J Natl Cancer Inst; 2023 Jun; 115(6):613-618. PubMed ID: 36943367
[TBL] [Abstract][Full Text] [Related]
4. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
Atkins MB; Abu-Sbeih H; Ascierto PA; Bishop MR; Chen DS; Dhodapkar M; Emens LA; Ernstoff MS; Ferris RL; Greten TF; Gulley JL; Herbst RS; Humphrey RW; Larkin J; Margolin KA; Mazzarella L; Ramalingam SS; Regan MM; Rini BI; Sznol M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36175037
[TBL] [Abstract][Full Text] [Related]
5. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.
Von Hoff DD; Clark GM; Coltman CA; Disis ML; Eckhardt SG; Ellis LM; Foti M; Garrett-Mayer E; Gönen M; Hidalgo M; Hilsenbeck SG; Littlefield JH; LoRusso PM; Lyerly HK; Meropol NJ; Patel JD; Piantadosi S; Post DA; Regan MM; Shyr Y; Tempero MA; Tepper JE; Von Roenn J; Weiner LM; Young DC; Vu NV
Clin Cancer Res; 2021 Oct; 27(20):5472-5481. PubMed ID: 34312215
[TBL] [Abstract][Full Text] [Related]
6. Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.
Pietanza MC; Basch EM; Lash A; Schwartz LH; Ginsberg MS; Zhao B; Shouery M; Shaw M; Rogak LJ; Wilson M; Gabow A; Latif M; Lin KH; Wu Q; Kass SL; Miller CP; Tyson L; Sumner DK; Berkowitz-Hergianto A; Sima CS; Kris MG
J Clin Oncol; 2013 Jun; 31(16):2004-9. PubMed ID: 23630218
[TBL] [Abstract][Full Text] [Related]
7. Resampling phase III data to assess phase II trial designs and endpoints.
Sharma MR; Karrison TG; Jin Y; Bies RR; Maitland ML; Stadler WM; Ratain MJ
Clin Cancer Res; 2012 Apr; 18(8):2309-15. PubMed ID: 22287601
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trials: a long-term investment with promising returns.
Sharma MR; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the yield of phase II combination therapy trials in medical oncology.
Maitland ML; Hudoba C; Snider KL; Ratain MJ
Clin Cancer Res; 2010 Nov; 16(21):5296-302. PubMed ID: 20837695
[TBL] [Abstract][Full Text] [Related]
10. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
[TBL] [Abstract][Full Text] [Related]
11. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.
Walter RB; Appelbaum FR; Tallman MS; Weiss NS; Larson RA; Estey EH
Blood; 2010 Oct; 116(14):2420-8. PubMed ID: 20538802
[TBL] [Abstract][Full Text] [Related]
12. Recommended changes to oncology clinical trial design: revolution or evolution?
Ratain MJ; Humphrey RW; Gordon GB; Fyfe G; Adamson PC; Fleming TR; Stadler WM; Berry DA; Peck CC
Eur J Cancer; 2008 Jan; 44(1):8-11. PubMed ID: 17981025
[No Abstract] [Full Text] [Related]
13. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
Chabner BA; Ratain MJ
Clin Cancer Res; 2007 Nov; 13(21):6540. PubMed ID: 17975169
[No Abstract] [Full Text] [Related]
14. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
15. Publication outcomes of phase II oncology clinical trials.
Hoeg RT; Lee JA; Mathiason MA; Rokkones K; Serck SL; Crampton KL; Emmel AE; Severson EA; Go RS
Am J Clin Oncol; 2009 Jun; 32(3):253-7. PubMed ID: 19349853
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
17. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
18. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
Michaelis LC; Ratain MJ
Clin Cancer Res; 2007 Apr; 13(8):2400-5. PubMed ID: 17438099
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
